A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
This study has been completed.
First Posted: May 12, 2010
Last Update Posted: November 21, 2017
Information provided by:
This is an open-label, single or multiple center study to determine the interaction of rifampin with navitoclax (ABT-263) in approximately 12 subjects with cancer.
|Lymphoma, Including Chronic Lymphocytic Leukemia Solid Tumors||Drug: navitoclax Drug: Rifampin||Phase 1|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax)|
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources: Lymphosarcoma Chronic Lymphocytic Leukemia Leukemia, B-cell, ChronicU.S. FDA Resources
Further study details as provided by AbbVie:
Primary Outcome Measures:
- To determine the effect of rifampin on the pharmacokinetics of navitoclax. [ Time Frame: Weekly ]
Secondary Outcome Measures:
- To determine the safety of navitoclax when administered alone and in combination with rifampin in these patients. [ Time Frame: Daily ]
|Study Start Date:||May 2010|
|Study Completion Date:||May 2011|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
|Experimental: Arm A (navitoclax and rifampin)||
Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
Other Name: ABT-263, navitoclaxDrug: Rifampin
Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
Contacts and Locations
No Contacts or Locations Provided